We are live on ! Find out more
CC

Callan Capital Portfolio holdings

AUM $1.35B
1-Year Est. Return 8.35%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$477M
AUM Growth
+$6.42M
Cap. Flow
-$17.8M
Cap. Flow %
-3.74%
Top 10 Hldgs %
75.49%
Holding
73
New
5
Increased
26
Reduced
20
Closed
3

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$1.39M
2
PRF icon
Invesco FTSE RAFI US 1000 ETF
PRF
+$1.35M
3
SDY icon
State Street SPDR S&P Dividend ETF
SDY
+$1.21M
4
FTGC icon
First Trust Global Tactical Commodity Strategy Fund
FTGC
+$968K
5
MINT icon
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
+$815K

Top Sells

Rank Stock Value
1
VGK icon
Vanguard FTSE Europe ETF
VGK
+$5.04M
2
EWJ icon
iShares MSCI Japan ETF
EWJ
+$1.71M
3
VWO icon
Vanguard FTSE Emerging Markets ETF
VWO
+$1.58M
4
EPP icon
iShares MSCI Pacific ex Japan ETF
EPP
+$1.36M
5
HALO icon
Halozyme
HALO
+$920K

Sector Composition

Rank Sector Weight
1 Miscellaneous 97.04%
2 Healthcare 2.02%
3 Real Estate 0.38%
4 Consumer Staples 0.23%
5 Materials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBFI
51
DELISTED
MB Financial Corp
MBFI
$541K 0.11%
15,705
– –
KND
52
DELISTED
Kindred Healthcare
KND
$537K 0.11%
26,468
– –
DSI icon
53
iShares MSCI KLD 400 Social ETF
DSI
$5.53B
$500K 0.1%
13,138
– –
ILMN icon
54
Illumina
ILMN
$32.6B
$435K 0.09%
2,048
+411
+25% +$80.3K
SPY icon
55
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$367K 0.08%
1,784
– –
TSLA icon
56
Tesla
TSLA
$1.38T
$357K 0.07%
19,950
-195
-1% -$3.08K
RGLS
57
DELISTED
Regulus Therapeutics
RGLS
$354K 0.07%
+269
New +$434K
IVV icon
58
iShares Core S&P 500 ETF
IVV
$898B
$325K 0.07%
1,570
+550
+54% +$116K
VDE icon
59
Vanguard Energy ETF
VDE
$10.7B
$313K 0.07%
2,930
– –
DLN icon
60
WisdomTree US LargeCap Dividend Fund
DLN
$6.35B
$273K 0.06%
7,520
– –
EFA icon
61
iShares MSCI EAFE ETF
EFA
$79.6B
$220K 0.05%
3,468
-208
-6% -$13.8K
ASRT
62
DELISTED
Assertio
ASRT
$215K 0.05%
167
– –
ACAD icon
63
Acadia Pharmaceuticals
ACAD
$5.02B
$209K 0.04%
5,000
-5,000
-50% -$194K
IMUC
64
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$143K 0.03%
7,598
-500
-6% -$9.62K
CRDF icon
65
Cardiff Oncology
CRDF
$73.1M
$115K 0.02%
+157
New +$111K
SEEL
66
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
HEPA
67
DELISTED
Hepion Pharmaceuticals
HEPA
– –
0
– –
BIOC
68
DELISTED
Biocept, Inc.
BIOC
$43K 0.01%
1
– –
ZGNX
69
DELISTED
Zogenix, Inc.
ZGNX
$17K ﹤0.01%
+1,250
New +$15.3K
AAPL icon
70
Apple
AAPL
$4.67T
– –
-12,124
Closed -$377K
HALO icon
71
Halozyme
HALO
$12B
– –
-64,431
Closed -$920K
SRE icon
72
Sempra
SRE
$55.1B
– –
-4,860
Closed -$265K
1 2
3

Similar funds

MBA
Maple-Brown Abbott Barangaroo, Australia $1.47B AUM 27.26% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
AP
Adero Partners Pleasanton, California $1.53B AUM 5.52% 1-Year Est. Return
MW
Marcum Wealth Cleveland, Ohio $1.16B AUM 6.7% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
PAME
Parvus Asset Management Europe London, United Kingdom $1.67B AUM

Callan Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Callan Capital held 73 positions worth $477M, up 1.4% from $470M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Callan Capital withdrew a net $17.8M in Q2 2015, closing 3 positions and reducing 20 holdings. Its most notable exit was Halozyme, an estimated $920K position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 97% of assets, down from 97% a quarter earlier, followed by Healthcare and Real Estate.

Against the trend, Callan Capital opened a new position in PIMCO Enhanced Short Maturity Active Exchange-Traded Fund worth $815K.

  • Callan Capital's largest Q2 2015 buy was PIMCO Enhanced Short Maturity Active Exchange-Traded Fund: 8,054 shares worth $815K.
  • Callan Capital added most to Becton Dickinson in Q2 2015, an estimated $1.39M increase.
  • Callan Capital's biggest Q2 2015 reduction was Vanguard FTSE Europe ETF, cutting an estimated $5.04M.
  • Callan Capital fully exited Halozyme in Q2 2015, selling an estimated $920K.
  • Callan Capital's ten largest holdings make up 75% of its $477M portfolio in Q2 2015.
  • Callan Capital opened 5 new positions and closed 3 in Q2 2015.
  • Callan Capital's portfolio value rose 1.4% quarter-over-quarter to $477M.

Based on Callan Capital's 13F filing for Q2 2015, filed 13 Aug 2015.